Novella CMD i London. På børsen er man ikke særlig overbeviste (-5%). Meddelelsen om hovedpunkterne på CMD var i hvert fald ret overordnet jargon.
Key highlights of the strategic ambitions for 20301 are:
Grow and diversify pipeline
- Launch >5 multi-blockbusters by 2030 and deliver >150 bDKK2 pipeline sales in 2035
- ≥5 Phase 3 programmes in obesity and diabetes3
- ≥5 Phase 3 programmes in other TAs3
Drive sustainable growth
- Deliver 2026-30 revenue CAGR in line with industry peers1
- Scale capacity to be able to serve 10x more people with obesity on oral GLP-1
- Serve >60m patients globally by 2030
Deliver attractive returns
- Maintain a broadly stable operating margin1
- Maintain an attractive dividend per share